| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD.V98.13.3569 |
| P698 | PubMed publication ID | 11739158 |
| P50 | author | Sylvie Chevret | Q42698968 |
| Hans Joachim Deeg | Q75039559 | ||
| P2093 | author name string | Remberger M | |
| Socié G | |||
| Blaise D | |||
| Ruutu T | |||
| Sullivan KM | |||
| Martin PJ | |||
| Clift RA | |||
| Devergie A | |||
| Michallet M | |||
| Ringden O | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| myeloid leukemia | Q11688946 | ||
| P304 | page(s) | 3569-3574 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | |
| P478 | volume | 98 |
| Q46577696 | A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors |
| Q37420496 | Acute graft-versus-host disease: from the bench to the bedside |
| Q35556270 | Aims of conditioning |
| Q35953264 | Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review |
| Q38248427 | Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective |
| Q35964204 | Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care |
| Q35560205 | Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes |
| Q79719156 | Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome |
| Q37810098 | Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies |
| Q80116846 | Allogeneic myeloablative transplantation for patients aged 50 years and over |
| Q35058700 | Allogeneic stem cell transplantation for chronic myeloid leukemia |
| Q36269924 | Allogeneic transplantation for chronic myelogenous leukemia |
| Q81634814 | Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group |
| Q41607636 | Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study |
| Q80466932 | Autologous bone marrow transplantation for children with AML in first remission |
| Q35555709 | Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature |
| Q37370649 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. |
| Q34668052 | Busulfan in hematopoietic stem cell transplantation |
| Q52585551 | CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. |
| Q59809962 | CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia |
| Q37181682 | Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings |
| Q35633858 | Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. |
| Q34617628 | Chronic myelogenous leukemia: treatment and monitoring |
| Q37140698 | Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. |
| Q35202316 | Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia |
| Q53038103 | Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. |
| Q38015268 | Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia |
| Q39306717 | Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia |
| Q33917170 | Conditioning regimens for hematopoietic cell transplantation: one size does not fit all |
| Q86941791 | Conditioning regimens for refractory acute myeloid leukaemia |
| Q38229633 | Conditioning regimens in acute myeloid leukemia |
| Q44578369 | Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. |
| Q80427674 | Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study |
| Q44571765 | Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias |
| Q80510512 | DNA-binding agents |
| Q38105635 | Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation |
| Q35981530 | Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma |
| Q42380314 | Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation. |
| Q44791851 | Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. |
| Q35809873 | Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy |
| Q37061964 | Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. |
| Q48085574 | Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study |
| Q24235525 | Hepatic late adverse effects after antineoplastic treatment for childhood cancer |
| Q93096849 | Hepatic late adverse effects after antineoplastic treatment for childhood cancer |
| Q35112199 | High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia |
| Q90613780 | Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management |
| Q89777718 | Identification of a murine CD45-F4/80lo HSC-derived marrow endosteal cell associated with donor stem cell engraftment |
| Q45909230 | Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. |
| Q44750603 | Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. |
| Q35136616 | Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies |
| Q48733875 | Intractable diffuse alopecia caused by multifactorial side-effects in treatment of acute lymphocytic leukemia: connection to iatrogenic failure of estrogen secretion |
| Q44451164 | Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity |
| Q37810122 | Late complications after hematopoietic stem cell transplantation |
| Q35110623 | Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. |
| Q90733679 | Long-term Effects of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Lymphoblastic Leukemia |
| Q88088400 | Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised |
| Q44323790 | Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias |
| Q46910179 | Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma |
| Q39376553 | Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years |
| Q52905842 | Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. |
| Q35739130 | Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY |
| Q73120803 | Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia |
| Q92769496 | Modulated volumetric arc therapy for total marrow irradiation: A feasibility study in the oncology hospital of CMN SXXI from a medical physics approach |
| Q35574536 | Myeloablative conditioning regimens for AML allografts: 30 years later |
| Q41039242 | Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. |
| Q35064139 | New approaches to hematopoietic cell transplantation in oncology |
| Q37828009 | Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant |
| Q84405861 | Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT |
| Q40190932 | Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. |
| Q43980367 | Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town |
| Q47923841 | Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood |
| Q82596474 | Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation |
| Q50510263 | Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. |
| Q83200302 | Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT |
| Q35058686 | Prognostic factors in chronic myeloid leukemia: allografting |
| Q37370651 | Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation |
| Q33786982 | Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation |
| Q82645441 | Quantitative ultrasound detects bone changes following bone marrow transplantation in pediatric subjects with hematological diseases: a longitudinal study |
| Q44571762 | Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study |
| Q74447668 | Recent publications in hematological oncology |
| Q33680218 | Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia |
| Q81359224 | Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation |
| Q33348605 | Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. |
| Q46365018 | Should busulfan-containing regimen be avoided for young female patients undergoing hematopoietic stem cell transplantation? |
| Q47124626 | Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity |
| Q80471824 | The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study |
| Q54978683 | The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. |
| Q44383228 | The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation |
| Q44619711 | The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia |
| Q91859903 | The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience |
| Q35610850 | The therapy of relapsed acute leukaemia in adults |
| Q35103643 | The war on cancer: a report from the front lines |
| Q37808638 | Total body irradiation (TBI) in pediatric patients. A single-center experience after 30 years of low-dose rate irradiation. |
| Q99202596 | Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by th |
| Q50529233 | Total body irradiation and melphalan as a conditioning regimen for children with hematological malignancies undergoing transplantation with stem cells from HLA-identical related donors. |
| Q87417746 | Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS |
| Q34288677 | Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. |
| Q100762129 | Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study |
Search more.